Bulk Pharmaceutical API Sources for FEMARA

Bulk Pharmaceutical API Sources for FEMARA

Vendor	Vendor Homepage	Vendor Sku	API Url
Hangzhou APIChem Technology		AC-1193
AKos Consulting & Solutions		AKOS005145822
Oakwood Products		036495
Amadis Chemical		A25380

FEMARA Bulk API Sourcing Landscape

Last updated: February 19, 2026

This analysis outlines the current landscape of bulk Active Pharmaceutical Ingredient (API) sourcing for Femara (letrozole). It details key manufacturers, patent expiry, and the implications for generic competition.

What is Femara and its Active Ingredient?

Femara is a non-steroidal aromatase inhibitor used primarily for the treatment of hormone receptor-positive breast cancer in postmenopausal women. Its active pharmaceutical ingredient is letrozole. Letrozole works by blocking the enzyme aromatase, which is responsible for converting androgens into estrogens. Lowering estrogen levels can slow or stop the growth of certain types of breast cancer.

The chemical name for letrozole is 4,4′-(1H-1,2,4-triazol-1-ylmethylene)bis(benzonitrile). Its molecular formula is C17H11N5, and its molecular weight is 285.30 g/mol.

What is the Patent Status of Femara?

The primary patent protecting Femara (letrozole) in the United States, U.S. Patent No. 4,963,570, was granted on October 17, 1990, and expired on October 17, 2007. This patent covered the compound letrozole. Novartis AG was the original innovator company.

While the primary compound patent has long expired, secondary patents, such as those related to specific formulations or methods of use, may have existed or been granted. However, the expiration of the core compound patent is the most significant factor for generic API sourcing and market entry.

Who are the Key Bulk API Manufacturers for Letrozole?

The manufacturing of bulk letrozole API is dominated by companies with strong chemical synthesis capabilities, particularly in India and China, which are global hubs for generic API production. These manufacturers supply the API to generic drug formulators worldwide.

Major Manufacturers and Suppliers:

• Divi’s Laboratories Ltd. (India): A significant player in the API market, Divi’s is known for its large-scale production capabilities and diverse product portfolio, which includes letrozole. The company has a strong regulatory track record with filings in major markets.
• Laurus Labs Ltd. (India): Lorus Labs is another prominent Indian API manufacturer with a substantial presence in various therapeutic areas, including oncology. They are a key supplier of APIs to global pharmaceutical companies.
• Sun Pharmaceutical Industries Ltd. (India): As one of the largest pharmaceutical companies globally, Sun Pharma also manufactures and supplies a range of APIs, including letrozole, for both its own formulations and for other generic manufacturers.
• Dr. Reddy’s Laboratories Ltd. (India): Dr. Reddy’s is a multinational pharmaceutical company that produces and markets a wide range of branded and generic formulations and APIs, including letrozole.
• Zydus Lifesciences Ltd. (formerly Cadila Healthcare) (India): This Indian pharmaceutical giant also has API manufacturing capabilities and is a supplier of letrozole.
• Alkem Laboratories Ltd. (India): Alkem is a significant domestic and international player in the pharmaceutical industry, with API manufacturing operations that include letrozole.
• Chinese Manufacturers: Several Chinese API manufacturers also produce letrozole. Companies such as Hospira (now part of Pfizer), Zhejiang Huahai Pharmaceutical Co., Ltd., and Jiangsu Hengrui Medicine Co., Ltd. have been involved in the production and supply of letrozole API. The specific list of active Chinese suppliers can fluctuate based on regulatory approvals and market demand.

These manufacturers typically operate under Good Manufacturing Practices (GMP) and supply API that meets pharmacopoeial standards (e.g., USP, EP). Their ability to produce high-quality letrozole API at scale and competitive prices is crucial for the generic pharmaceutical market.

What is the Current Market Status and Generic Competition?

Following the expiration of the primary patent for Femara, the market has seen significant generic competition. Numerous pharmaceutical companies have launched generic versions of letrozole tablets, leading to a substantial decrease in prices compared to the innovator product.

Key aspects of the generic market:

• Multiple Generic Entrants: The market is characterized by a large number of generic manufacturers offering letrozole tablets in various strengths, most commonly 2.5 mg.
• Price Erosion: Generic competition has driven significant price erosion, making letrozole more accessible.
• Global Supply Chain: Bulk API manufacturers in India and China serve as the backbone of this generic supply chain, providing letrozole API to formulators across the globe.
• Regulatory Approvals: Generic drug manufacturers must obtain approvals from regulatory authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national bodies. This includes demonstrating bioequivalence and the quality of the API used.

The availability of multiple, reliable bulk API sources is a key enabler of this competitive generic market.

What are the Regulatory Considerations for API Sourcing?

Sourcing bulk letrozole API requires strict adherence to regulatory standards to ensure the safety, efficacy, and quality of the final drug product. Key regulatory considerations include:

• Good Manufacturing Practices (GMP): API manufacturers must comply with GMP guidelines established by regulatory bodies like the FDA, EMA, and WHO. This ensures consistent quality and control throughout the manufacturing process.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. A DMF contains confidential, detailed information about the manufacturing, processing, packaging, and storing of the API. Generic drug applicants can then reference these DMFs in their own marketing applications.
• Inspections and Audits: Regulatory agencies conduct inspections of API manufacturing facilities to ensure compliance with GMP. Pharmaceutical companies also conduct their own audits of API suppliers.
• Pharmacopoeial Standards: The API must meet the specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP) or the European Pharmacopoeia (EP). These standards define purity, identity, strength, and other critical quality attributes.
• Impurity Profiling: Comprehensive impurity profiling is essential. Manufacturers must identify, quantify, and control any process-related impurities or degradation products to meet regulatory limits.
• Traceability and Supply Chain Integrity: Maintaining a secure and traceable supply chain is critical to prevent counterfeit APIs and ensure product integrity from the API manufacturer to the finished dosage form.

For companies looking to source letrozole API, verifying the regulatory compliance and quality management systems of potential suppliers is paramount.

What are the Challenges and Opportunities in Letrozole API Sourcing?

Challenges:

• Quality Control: Ensuring consistent API quality from multiple suppliers, especially given geographical distances and varying regulatory oversight in different regions, remains a challenge.
• Supply Chain Volatility: Geopolitical events, raw material shortages, or unexpected production disruptions at a key API manufacturer can impact supply availability and pricing.
• Regulatory Scrutiny: Increased regulatory scrutiny on API manufacturing, particularly concerning impurities and supply chain transparency, can lead to delays or require significant investment in compliance.
• Price Pressure: The highly competitive generic market puts continuous downward pressure on API prices, requiring manufacturers to optimize production costs.

Opportunities:

• Emerging Markets: Growing demand for oncology treatments in emerging markets presents opportunities for API suppliers and generic formulators.
• Vertical Integration: Some generic companies may pursue vertical integration by establishing or acquiring API manufacturing capabilities to secure supply and control costs.
• Technological Advancements: Innovations in chemical synthesis and process optimization can lead to more efficient and cost-effective API production, creating a competitive advantage.
• Strategic Partnerships: Forming strategic partnerships between API manufacturers and generic drug developers can streamline the path to market and ensure reliable supply.

Key Takeaways

• Femara’s primary compound patent has expired, allowing for extensive generic competition.
• The bulk API for letrozole is predominantly manufactured in India and China by companies like Divi’s Laboratories, Laurus Labs, Sun Pharma, and several Chinese entities.
• API sourcing must adhere to strict GMP standards and regulatory requirements, including DMF submissions.
• The generic letrozole market is highly competitive, characterized by price erosion and multiple global suppliers.
• Challenges include maintaining consistent quality, navigating supply chain volatility, and managing regulatory compliance, while opportunities lie in emerging markets and technological advancements.

Frequently Asked Questions

1. Which regulatory bodies oversee the API manufacturers of letrozole? Regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and national health authorities in India, China, and other importing countries oversee the API manufacturers.

2. What is the typical purity requirement for bulk letrozole API? Bulk letrozole API typically must meet pharmacopoeial standards, such as the USP or EP, which specify a minimum purity level, often greater than 98.0% or 99.0%, along with strict limits for specified and unspecified impurities.

3. Can a generic drug company source letrozole API from multiple manufacturers simultaneously? Yes, generic drug companies can and often do source letrozole API from multiple qualified manufacturers to ensure supply chain security and manage costs, provided all suppliers meet regulatory and quality standards.

4. What is the role of a Drug Master File (DMF) in letrozole API sourcing? A DMF allows API manufacturers to provide confidential, detailed manufacturing information directly to regulatory authorities, which generic drug applicants can then reference in their marketing applications, simplifying the regulatory review process for the finished drug product.

5. Are there any geographical restrictions on where letrozole API can be sourced from? While there are no explicit geographical restrictions imposed by patent law for sourcing generic APIs, regulatory approval is jurisdiction-specific. An API manufacturer's facility must be approved by the regulatory agency in the country where the finished drug product will be marketed.

Citations

[1] U.S. Patent No. 4,963,570. (1990). U.S. Patent and Trademark Office. [2] World Health Organization. (n.d.). Good manufacturing practices for pharmaceutical products: General information. [3] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). [4] United States Pharmacopeia. (n.d.). USP Drug Standards. [5] European Pharmacopoeia. (n.d.). European Pharmacopoeia standards.